PCSK9 and endothelial dysfunction: Inhibition of PCSK9 has also been shown to reduce endothelial dysfunction and the size of atherosclerotic lesions, suggesting a potential therapeutic target for the treatment of atherosclerotic diseases [109] (Fig. 3).